New Enterprise Associates
http://www.nea.com/Home/New Enterprise Associates is a venture capital firm based in Baltimore, MD. The firm has backed more than 160 companies that have gone public and invested in more than 230 companies that have been successfully merged or acquired. NEA focuses its investments in the information technology, healthcare, and energy technology industries. While NEA makes a majority of its investments in the United States, the firm invests around the world in China and India. The firm was founded in 1978.
View Older Stories View More Recent Stories
-
Fabric8Labs Closes $50M Series B Financing for Electrochemical Additive Manufacturing Technology
-
flox Raises $27 Million, Introduces Open Source Platform to Bring Nix to Everyone
-
Form SC 13G/A Tuya Inc. Filed by: New Enterprise Associates 14, L.P.
-
SpyGlass Pharma Unveils 6-Month Data from the First-In-Human Trial of Its Innovative Drug Delivery Platform for Chronic Eye Conditions
-
AviadoBio Announces Appointment of Jeff Goater as Chair of the Board of Directors
-
Stride Health Recognized As One of Built In's Best Places to Work in 2023
-
NEA Closes On Two Funds Totaling $6.2 Billion
-
Form SC 13D/A Arcellx, Inc. Filed by: New Enterprise Associates 15, L.P.
-
Form SC 13D/A MINERVA SURGICAL INC Filed by: NEW ENTERPRISE ASSOCIATES 13 LP
-
MBX Biosciences to Participate in the SVB Securities Global Biopharma Conference
-
SetPoint Medical Announces $80M Preferred Stock Financing to Advance Company’s Novel Treatment for Autoimmune Diseases
-
U.S. startup Outrider raises $73 million to scale up autonomous yard trucks
-
Outrider raises $73 million Series C financing to accelerate the adoption of autonomous distribution yard operations
-
Stablix Appoints Douglas Williams, Ph.D., to Board of Directors
-
BMO Receives Regulatory Approval to Acquire Bank of the West
-
New Feature From Topia Allows HR And Global Mobility Professionals To Better Manage Group, Project Team And Bulk Moves
-
Form SC 13D/A Oyster Point Pharma, Filed by: New Enterprise Associates 14, L.P.
-
MBX Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
Lumos Pharma to Participate in 12th Annual LifeSci Partners Corporate Access Event January 9-11, 2023
-
Lumos Pharma to Participate in 12th Annual LifeSci Partners Corporate Access Event January 9-11, 2023
-
GoodLeap Forms Advisory Council with Diverse Leadership and Expertise
-
Minerva Surgical (UTRS) Prices 146.63M Share Private Placement at $0.205/sh
-
Minerva Surgical Announces $30 Million Private Placement of Common Stock Led by Accelmed Partners
-
Form 4 Arcellx, Inc. For: Dec 20 Filed by: New Enterprise Associates 15, L.P.
-
Atara Biotherapeutics Announces Changes to Its Board of Directors
-
Form SC 13D/A Eargo, Inc. Filed by: New Enterprise Associates 15, L.P.
-
Black Diamond Therapeutics (BDTX) Announces Spinout of Launchpad Therapeutics, Inc., an Antibody-Focused Precision Oncology Company
-
Black Diamond Therapeutics Announces Spinout of Launchpad Therapeutics, Inc., an Antibody-Focused Precision Oncology Company
-
Lumos Pharma, Inc. (LUMO) Announces KOL Review of Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients
-
KOL Review of Lumos Pharma’s Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients
-
KOL Review of Lumos Pharma’s Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients
-
Celcuity Closes $100 Million Private Placement
-
IMAS Announces Dr Scott Gottlieb as Keynote Speaker for ACCESS 2023 in Miami Beach
-
Timescale Announces Appointment of Virginia Liu as Chief Marketing Officer
-
Stride Health Appoints Peter V. Lee, Former Executive Director of Covered California, to Board of Directors
-
Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib for the Treatment of HR+/HER2- Advanced Breast Cancer
-
Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHD
-
Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHD
-
Escient Pharmaceuticals Announces $120 Million Series C Financing
-
Lumos Pharma to Participate in the Piper Sandler 34th Annual Healthcare Conference
-
Lumos Pharma to Participate in the Piper Sandler 34th Annual Healthcare Conference
-
Form SC 13D/A Oyster Point Pharma, Filed by: New Enterprise Associates 14, L.P.
-
Form 4 IonQ, Inc. For: Nov 16 Filed by: New Enterprise Associates 15, L.P.
-
Timescale advances best-in-class price performance for developers with launch of new object storage layer on Amazon S3
-
Braintrust Tutors Adds Notable Investors Scott Sandell and John Chambers
-
Braintrust Tutors Adds Notable Investors Scott Sandell and John Chambers
-
Affordability Education Gap Is No. 1 Barrier to Increasing Independent and Gig Worker Health Coverage Rate, Per New Stride Health Survey
-
New Wave Foods® Announces Partnership with Restauranteur, Influencer and Television Personality Chef Brian Duffy
-
ReCode Therapeutics Establishes Scientific Advisory Board
-
MBX Biosciences Closes $115 Million Series B Financing to Advance Development of Endocrine Disease Programs

